This methodical approach may be particularly promising for the reevaluation of the role of P2X7 in cancer as well as in inflammatory and neurodegenerative diseases where conflicting results have been obtained so far using knock-out models and/or repetitive administration of small-molecule inhibitors. Here, P2RX7 is linked to neurodegenerative disease.